 |
|
|
| |
SURVEYOR-II, Part 4: Glecaprevir/Pibrentasvir [ABT493+ABT530] Demonstrates High SVR Rates in Patients With HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Following an 8-Week Treatment Duration
|
| |
| |
Late Breaker Poster Today
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Tarek Hassanein1, David Wyles2, Stanley Wang3, Paul Y Kwo4, Mitchell L Shiff man5, Ziad Younes6, Susan Greenbloom7, Catherine A Stedman8,
Joseph Sasadeusz9, Humberto Aguilar10, Jeong Heo11, Ran Liu3, Teresa I Ng3, Chih-Wei Lin3, Federico Mensa3
1Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States; 2Denver Health Medical Center, Denver, Colorado, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Indiana University School of Medicine, Indianapolis, Indiana, United States; 5Liver Institute of Virginia, Bon Secours Health System, Newport News and Richmond, Virginia, United States; 6GastroOne, Germantown, Tennessee, United States; 7Toronto Digestive Disease Associates, Toronto, Ontario, Canada; 8Christchurch Hospital and University of Otago, Christchurch, New Zealand; 9Island Health Authority, Secti on of Infectious Diseases, Victoria, British Columbia, Canada; 10Louisiana Research Center, Shreveport, Louisiana, United States; 11College of Medicine, Pusan National University and Medical Research Insti tute, Pusan Nati onal University Hospital, Busan, Republic of Korea
from Jules: there appears to be only 1 viral failure, a relapser
|
| |
|
|
|
|
|
